104 related articles for article (PubMed ID: 21415283)
1. Reevaluation of moxifloxacin pharmacokinetics and their direct effect on the QT interval.
Grosjean P; Urien S
J Clin Pharmacol; 2012 Mar; 52(3):329-38. PubMed ID: 21415283
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic and concentration--QTc models for moxifloxacin: pooled analysis of 20 thorough QT studies.
Florian JA; Tornøe CW; Brundage R; Parekh A; Garnett CE
J Clin Pharmacol; 2011 Aug; 51(8):1152-62. PubMed ID: 21228407
[TBL] [Abstract][Full Text] [Related]
3. Statistical characteristics of moxifloxacin-induced QTc effect.
Yan LK; Zhang J; Ng MJ; Dang Q
J Biopharm Stat; 2010 May; 20(3):497-507. PubMed ID: 20358432
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of moxifloxacin in plasma and tissue of morbidly obese patients.
Kees MG; Weber S; Kees F; Horbach T
J Antimicrob Chemother; 2011 Oct; 66(10):2330-5. PubMed ID: 21729931
[TBL] [Abstract][Full Text] [Related]
5. The use of beat-to-beat electrocardiogram analysis to distinguish QT/QTc interval changes caused by moxifloxacin from those caused by vardenafil.
Fossa AA; Langdon G; Couderc JP; Zhou M; Darpo B; Wilson F; Wallis R; Davis JD
Clin Pharmacol Ther; 2011 Sep; 90(3):449-54. PubMed ID: 21814193
[TBL] [Abstract][Full Text] [Related]
6. A statistical assessment of QT data following placebo and moxifloxacin dosing in thorough QT studies.
Stylianou A; Roger J; Stephens K
J Biopharm Stat; 2008; 18(3):502-16. PubMed ID: 18470759
[TBL] [Abstract][Full Text] [Related]
7. QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome.
Chen X; Cass JD; Bradley JA; Dahm CM; Sun Z; Kadyszewski E; Engwall MJ; Zhou J
Br J Pharmacol; 2005 Nov; 146(6):792-9. PubMed ID: 16158069
[TBL] [Abstract][Full Text] [Related]
8. Moxifloxacin versus placebo modeling of the QT interval.
Grosjean P; Urien S
J Pharmacokinet Pharmacodyn; 2012 Apr; 39(2):205-15. PubMed ID: 22350254
[TBL] [Abstract][Full Text] [Related]
9. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: implications for blinding in active-controlled cardiac repolarization studies.
Mason JW; Florian JA; Garnett CE; Moon TE; Selness DS; Spaulding RR
J Clin Pharmacol; 2010 Nov; 50(11):1249-59. PubMed ID: 20145260
[TBL] [Abstract][Full Text] [Related]
11. Penetration of moxifloxacin into liver tissue.
Justinger C; Schilling MK; Kees MG; Kauffels A; Hirschmann K; Kopp B; Kees F; Kollmar O
Int J Antimicrob Agents; 2012 Jun; 39(6):505-9. PubMed ID: 22526014
[TBL] [Abstract][Full Text] [Related]
12. Application of a probabilistic method for the determination of drug-induced QT prolongation in telemetered cynomolgus monkeys: effects of moxifloxacin.
Holzgrefe HH; Cavero I; Buchanan LV; Gill MW; Durham SK
J Pharmacol Toxicol Methods; 2007; 55(3):227-37. PubMed ID: 17097307
[TBL] [Abstract][Full Text] [Related]
13. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single oral dose of moxifloxacin (400 mg and 800 mg) on ventricular repolarization in healthy subjects.
Démolis JL; Kubitza D; Tennezé L; Funck-Brentano C
Clin Pharmacol Ther; 2000 Dec; 68(6):658-66. PubMed ID: 11180026
[TBL] [Abstract][Full Text] [Related]
15. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.
Malik M; van Gelderen EM; Lee JH; Kowalski DL; Yen M; Goldwater R; Mujais SK; Schaddelee MP; de Koning P; Kaibara A; Moy SS; Keirns JJ
Clin Pharmacol Ther; 2012 Dec; 92(6):696-706. PubMed ID: 23149929
[TBL] [Abstract][Full Text] [Related]
16. Creation of a knowledge management system for QT analyses.
Tornøe CW; Garnett CE; Wang Y; Florian J; Li M; Gobburu JV
J Clin Pharmacol; 2011 Jul; 51(7):1035-42. PubMed ID: 20978278
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and bioavailability of moxifloxacin in calves following different routes of administrations.
Goudah A; Hasabelnaby S
Chemotherapy; 2010; 56(1):26-31. PubMed ID: 20197659
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and bioavailability of moxifloxacin in buffalo calves.
Pathania R; Sharma SK
Res Vet Sci; 2010 Aug; 89(1):108-12. PubMed ID: 20202656
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and pharmacodynamic evaluation of intravenous and enteral moxifloxacin in surgical intensive care unit patients.
Kees MG; Schaeftlein A; Haeberle HA; Kees F; Kloft C; Heininger A
J Antimicrob Chemother; 2013 Jun; 68(6):1331-7. PubMed ID: 23463212
[TBL] [Abstract][Full Text] [Related]
20. Period correction of the QTc of moxifloxacin with multiple predose baseline ECGs is the least variable of 4 methods tested.
Zhang X; Silkey M; Schumacher M; Wang L; Raval H; Caulfield JP
J Clin Pharmacol; 2009 May; 49(5):534-9. PubMed ID: 19287043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]